Premium
Micro RNA ‐155 is a biomarker of T‐cell activation and immune dysfunction in HIV ‐1‐infected patients
Author(s) -
Jin C,
Cheng L,
Höxtermann S,
Xie T,
Lu X,
Wu H,
SkaletzRorowski A,
Brockmeyer NH,
Wu N
Publication year - 2017
Publication title -
hiv medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.53
H-Index - 79
eISSN - 1468-1293
pISSN - 1464-2662
DOI - 10.1111/hiv.12470
Subject(s) - cd38 , interleukin 7 receptor , medicine , immune system , cd8 , peripheral blood mononuclear cell , flow cytometry , immunology , t cell , biomarker , il 2 receptor , biology , in vitro , microbiology and biotechnology , stem cell , biochemistry , cd34
Objectives Micro RNA ‐155 (miR‐155) regulates T‐cell differentiation and activation. It has also been associated with HIV infection. However, it remains unclear whether miR‐155 is related to the T‐cell response in HIV ‐infected individuals (e.g. T‐cell activation and exhaustion). Methods We performed a cross‐sectional study involving 121 HIV ‐1‐infected patients on highly active antiretroviral therapy ( HAART ) and 43 HAART ‐naïve patients. MiR‐155 levels in the peripheral blood were determined by quantitative reverse transcription–polymerase chain reaction ( PCR ). T‐cell immune activation, exhaustion, and homeostasis were measured by determining the expression of CD 38, programmed death 1 ( PD ‐1) and CD 127 via flow cytometry. Results The levels of miR‐155 in total peripheral blood mononuclear cells, CD 4 T cells and CD 8 T cells from HIV ‐1‐infected patients were increased ( P < 0.01). Nonresponders and HAART ‐naïve patients also exhibited a higher percentage of CD 8 + CD 38 + T cells and a lower percentage of CD 4 + CD 127 + and CD 8 + CD 127 + T cells ( P < 0.05). We also found higher levels of PD ‐1 expression on the CD 4 + and CD 8 + T cells of HIV ‐1‐infected patients ( P < 0.05). Conclusions Our findings suggest that miR‐155 levels in the peripheral blood of HIV ‐1‐infected patients are increased and associated with T‐cell activation. Therefore, miR‐155 is a potential biomarker of the immune response following HIV ‐1 infection.